Key facts
- This page summarizes David Silberman's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Jan 2024, 16:39.
David Silberman - 04 Jan 2024 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ORMP
- Reported as of
- 04 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Jan 2024, 16:39:04 UTC
- Prior SEC filing
- 31 May 2023
- Next SEC filing
- 18 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Silberman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Silberman filed Form 4 for ORAMED PHARMACEUTICALS INC. (ORMP) on 08 Jan 2024.
Change
- Previous filing in this sequence was filed on 31 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ORMP
transaction
Common Stock
Award
- Transaction value
- Shares
- +136,500
- Change %
- +59%
- Price
- Shares after
- 366,500
- Date
- 04 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents Restricted Stock Units ("RSUs") that will vest in equal quarterly installments of 11,375 over a three year period starting January 8, 2024. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.